Effect and mechanism of local radiotherapy combined with immune checkpoint inhibitor in the treatment of metastatic triple negative breast cancer

Qiong Lu, Fei Wang, Lei Yu, Ping Lv

Abstract

Triple negative breast cancer is highly sensitive to immunotherapy due to its high PD-L1 expression; however, many patients exhibit poor response or develop resistance. This study evaluates the efficacy and mechanism of local radiotherapy combined with PD 1/PD-L1 inhibitors in metastatic triple negative breast cancer treatment. A retrospective analysis of 40 patients divided into a combination group (local radiotherapy + PD-1/PD-L1 inhibitor) and a single-agent group (PD-1/PD-L1 inhibitor) was conducted. Clinical efficacy, progression-free survival, immune cytokine levels (Tumor necrosis factor-α, Interleukin-1, and Interleukin-8), and adverse effects were compared. Results showed that the combination therapy significantly improved clinical outcomes and prolonged progression-free survival without increasing toxicity. Patients receiving local radiotherapy and PD-1/PD-L1 inhibitors exhibited reduced immune cytokines, with no significant post-treatment increase in Tumor necrosis factor-α, Interleukin-1, and Interleukin-8 levels. These findings suggest that local radiotherapy enhances the effectiveness of PD-1/PD-L1 inhibitors in TNBC treatment without raising the risk of adverse effects.

Full Text:

PDF

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram

I, Jemal A, and Bray F. Global Cancer Statistics

: GLOBOCAN Estimates of Incidence and

Mortality Worldwide for 36 Cancers in 185

Countries. CA Cancer J Clin, 2021;71(3):209-249.

Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, and

Chen Y. Recent advances in therapeutic strategies for

triple-negative breast cancer. J Hematol Oncol,

;15(1):121.

Sun X, Tang H, Chen Y, Chen Z, Hu Z, Cui Z, Tao Y, Yuan

J, Fu Y, Zhuang Z, He Q, Li Q, Xu X, Wan X, Jiang

Y, and Mao Z. Loss of the receptors ER, PR and

HER2 promotes USP15-dependent stabilization of

PARP1 in triple-negative breast cancer. Nat Cancer,

;4(5):716-733.

Zhu H, Yang K, Yao H, Chen X, Yan S, He Y, Cao Y, Luo

J,

and Wang D. Multifunctional Nanoplatform

Mediated Chemo-Photothermal Therapy Combines

Immunogenic Cell Death with Checkpoint Blockade

to Combat Triple-Negative Breast Cancer and

Distant

Metastasis.

;18:3109-3124.

Int

J

Nanomedicine,

Gao C, Li H, Liu C, Xu X, Zhuang J, Zhou C, Liu L, Feng

F, and Sun C. Tumor Mutation Burden and Immune

Invasion Characteristics in Triple Negative Breast

Cancer: Genome High-Throughput Data Analysis.

Front Immunol, 2021;12:650491.

Chow R, Hasan S, Choi JI, Fox J, Chhabra AM, Marshall

DC, Bakst RL, and Simone CB 2nd. Effect of

treatment interruptions on overall survival in patients

with triple-negative breast cancer. J Natl Cancer Inst,

;115(9):1029-1035.

Marra A, and Curigliano G. Adjuvant and Neoadjuvant

Treatment of Triple-Negative Breast Cancer With

Chemotherapy. Cancer J, 2021;27(1):41-49.

Derakhshan F, and Reis-Filho JS. Pathogenesis of Triple

Negative Breast Cancer. Annu Rev Pathol,

;17:181-204.

Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG,

Park DW, Park J, Jeang JW, and Kang SC. Triple

negative breast cancer: epidemiology, molecular

mechanisms, and modern vaccine-based treatment

strategies. Biochem Pharmacol, 2023;212:115545.

Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S,

Murakami T, Zhang X, Sekhar SC, Kim S, Ryu S,

Knarr M, Vasilev SA, DiFeo A, Drapkin R, and

Hoon DSB. MiR-181a targets STING to drive PARP

inhibitor resistance in BRCA-mutated triple-negative

breast cancer and ovarian cancer. Cell Biosci,

;13(1):200.

Zhu Y, Liu Z, Gui L, Yun W, Mao C, Deng R, Yao Y, Yu

Q, Feng J, Ma H, and Bao W. Inhibition of CXorf56

promotes PARP inhibitor-induced cytotoxicity in

triple-negative breast cancer. NPJ Breast Cancer,

;9(1):34.

Teo ZL, O'Connor MJ, Versaci S, Clarke KA, Brown ER,

Percy LW, Kuykhoven K, Mintoff CP, Savas P,

Virassamy B, Luen SJ, Byrne A, Sant S, Lindeman

GJ, Darcy PK, and Loi S. Combined PARP and

WEE1 inhibition triggers anti-tumor immune

response in BRCA1/2 wildtype triple-negative breast

cancer. NPJ Breast Cancer, 2023;9(1):68.

Luo K, Yang L, Yan C, Zhao Y, Li Q, Liu X, Xie L, Sun

Q, and Li X. A Dual-Targeting Liposome Enhances

Triple-Negative

Breast

Chemoimmunotherapy

through

Cancer

Inducing

Immunogenic Cell Death and Inhibiting STAT3

Activation. Small, 2023;19(40):e2302834.

Kumar S, Chatterjee M, Ghosh P, Ganguly KK, Basu M,

and Ghosh MK. Targeting PD-1/PD-L1 in cancer

immunotherapy: An effective strategy for treatment

of triple-negative breast cancer (TNBC) patients.

Genes Dis, 2022;10(4):1318-1350.

Yu Y, Jin X, Zhu X, Xu Y, Si W, and Zhao J. PD-1/PD-L1

immune checkpoint inhibitors in metastatic triple

negative breast cancer: a systematic review and

meta-analysis. Front Immunol, 2023;14:1206689.

Liu C, Qian X, Yu C, Xia X, Li J, Li Y, Xie Y, Gao G, Song

Y, Zhang M, Xue H, Wang X, Sun H, Liu J, Deng

W, and Guo X. Inhibition of ATM promotes PD-L1

expression by activating JNK/c-Jun/TNF-α signaling

axis in triple-negative breast cancer. Cancer Lett,

;586:216642.

Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz

A, Sebra RP, Farkas AM, Gnjatic S, Hake A,

Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind

Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E,

Sharma P, Bhardwaj N, and Zhu J. Myeloid Cell

associated Resistance to PD-1/PD-L1 Blockade in

Urothelial Cancer Revealed Through Bulk and

Single-cell RNA Sequencing. Clin Cancer Res,

;27(15):4287-4300.

Zeng L, Ding S, Cao Y, Li C, Zhao B, Ma Z, Zhou J, Hu

Y, Zhang X, Yang Y, Duan G, Bian X, and Tian G.

A MOF-Based Potent Ferroptosis Inducer for

Enhanced Radiotherapy of Triple Negative Breast

Cancer. ACS Nano, 2023;17(14):13195-13210.

Banerji U, van Herpen CML, Saura C, Thistlethwaite F,

Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C,

de Vries EGE, Rottey S, Geenen J, Eskens F, Gil

Martin M, Mommers EC, Koper NP, and Aftimos P.

Trastuzumab duocarmazine in locally advanced and

metastatic solid tumours and HER2-expressing

breast cancer: a phase 1 dose-escalation and dose

expansion study. Lancet Oncol, 2019;20(8):1124

Huang R, Wang Z, Hong J, Wu J, Huang O, He J, Chen W,

Li Y, Chen X, and Shen K. Targeting cancer

associated adipocyte-derived CXCL8 inhibits triple

negative breast cancer progression and enhances theefficacy of anti-PD-1 immunotherapy. Cell Death

Dis, 2023;14(10):703.

Chen M, Bie L, and Ying J. Cancer cell-intrinsic PD-1: Its

role in malignant progression and immunotherapy.

Biomed Pharmacother, 2023;167:115514.

Ali LR, Lenehan PJ, Cardot-Ruffino V, Dias Costa A, Katz

MHG, Bauer TW, Nowak JA, Wolpin BM, Abrams

TA, Patel A, Clancy TE, Wang J, Mancias JD,

Reilley MJ, Stucky CH, Bekaii-Saab TS, Elias R,

Merchant N, Slingluff CL Jr, Rahma OE, and

Dougan SK. PD-1 Blockade Induces Reactivation of

Nonproductive T-Cell Responses Characterized by

NF-κB Signaling in Patients with Pancreatic Cancer.

Clin Cancer Res, 2024;30(3):542-553.

Dai D, Zhou H, Yin L, Ye F, Yuan X, You T, Zhao X, Long

W, Wang D, He X, Feng J, and Chen D. PELI1

promotes radiotherapy sensitivity by inhibiting

noncanonical NF-κB in esophageal squamous

cancer. Mol Oncol, 2022;16(6):1384-1401.

Liu Z, Zhao L, Liu H, Dong N, Zhou N, Zhang Y, Yin T,

He H, Gou J, Tang X, Yang L, and Gao S.

Norcantharidin liposome emulsion hybrid delivery

system enhances PD-1/PD-L1 immunotherapy by

agonizing the non-canonical NF-κB pathway. Int J

Pharm, 2022;628:122361.

Stenmark Tullberg A, Sjöström M, Tran L, Niméus E

Killander F, Kovács A, Lundstedt D, Holmberg Eand Karlsson P. Combining histological grade, TILs,

and the PD-1/PD-L1 pathway to identify

immunoenic tumors and de-escalate radiotherapy in

early breast cancer: a secondary analysis of a

randomized clinical trial[J]. J Immunother Cancer,

,11(5):e006618.

Yang X, en H, Li Z, Peng X and Fu J. Combinations of

radotherapy with immunotherapy in nasopharyngeal

carcinoma[J]. Int Immunopharmacol, 2023,125(Pt

A):111094.

Zhu Y, en J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang

S Lv Y,Li J, Zhang L, Hu Y, Liu M and Xi M.

Toripalimab combined with definitive

chemoradiotherapy in locally advanced oesophageal

squamous cell carcinoma (EC-CRT-001): a single

arm, phase 2 trial[J]. Lancet Oncol, 2023,24(4):371

Oyoshi , Du J, Sakai SA, Yamashita R, Okumura M,

Motegi A,Hojo H, Nakamura M, Hirata H, Sunakawa

H, Kotani D, Yano T, Kojima T, Nakamura Y,

Kojima M, Suzuki A, Zenkoh J, Tsuchihara K,

Akimoto T, Shibata A, Suzuki Y and Kageyama SI.

Comprehensive single-cell analysis demonstrates

radiotherapy-induced infiltration of macrophages

expressing immunosuppressive genes into tumor in

esophageal squamous cell carcinoma[J]. Sci Adv,

,9(50):eadh9069

Refbacks

  • There are currently no refbacks.